KPC Pharmaceuticals' (SHA:600422) attributable profit rose 20% to 648.1 million yuan in 2024 from 540.7 million yuan in 2023.
Earnings per share at the drug company increased 21% to 0.86 yuan from 0.71 yuan in the previous year, according to a Tuesday filing by parent China Resources Pharmaceutical (HKG:3320) with the Hong Kong bourse.
Revenue slipped 0.3% to 8.40 billion yuan from 8.43 billion yuan a year earlier.